Common side effects in this phase Nausea or queasy feeling Reduced appetite and early fullness Constipation or diarrhea Bloating, gas, or mild reflux Fatigue or headache, often related to lower calories, dehydration, or electrolyte changes What is not expected Severe or persistent vomiting, severe abdominal pain, fainting, or signs of dehydration should be discussed promptly with a healthcare provider
J Investig Dermatol 133:79
Hi Nackapan, Yes, I would agree with a lot of what you say
Because GIP receptor activation affects fat metabolism through pathways separate from appetite control, there is a theoretical basis for better weight maintenance at lower tirzepatide doses compared to equivalent semaglutide doses
Techniques such as modifying liposome composition, optimizing drug-loading methods, and designing drug-specific liposomes are being explored to enhance encapsulation [344]